Summary
DexCom, Inc. (DXCM) has filed a Form 8-K to provide preliminary, unaudited financial results for the fourth quarter and full fiscal year 2024, along with initial financial guidance for fiscal year 2025. These updates were shared during a presentation at the J.P. Morgan 43rd Annual Healthcare Conference on January 13, 2025, by CEO Kevin Sayer. Investors should note that these results are preliminary and subject to finalization during the preparation of the upcoming Form 10-K. The filing also contains forward-looking statements regarding revenue, gross profit margin, and operating margin, which are subject to inherent risks and uncertainties that could cause actual results to differ materially.
Key Highlights
- 1Preliminary, unaudited financial results for Q4 2024 and FY 2024 have been released.
- 2Initial financial outlook for fiscal year 2025 has been provided.
- 3The information was presented at the J.P. Morgan 43rd Annual Healthcare Conference on January 13, 2025.
- 4CEO Kevin Sayer delivered the remarks and presented the preliminary data.
- 5The reported results and guidance are subject to finalization and potential adjustments in the upcoming Form 10-K.
- 6The filing includes forward-looking statements concerning revenue, Non-GAAP Gross Profit Margin, and Non-GAAP Operating Margin for 2024 and 2025.
Frequently Asked Questions
No, the financial results for the fourth quarter and full fiscal year 2024 are preliminary and unaudited. They are subject to finalization as DexCom prepares its Annual Report on Form 10-K.
The filing provides preliminary revenue for Q4 and FY 2024, and initial financial outlook for FY 2025, including guidance on revenue, Non-GAAP Gross Profit Margin, and Non-GAAP Operating Margin.
This information was presented by CEO Kevin Sayer during remarks at the J.P. Morgan 43rd Annual Healthcare Conference on January 13, 2025.
The filing contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those anticipated due to factors detailed in DexCom's most recent SEC filings (Form 10-K and 10-Q).